APIS Assay Technologies Ltd expands bioinformatics expertise with acquisition of Beogenomics
APIS Assay Technologies Ltd, a company combining outstanding In Vitro Diagnostics (IVD) experience with integrated AI to develop biomarker-based diagnostic assays, have announced the acquisition of Beogenomics, a specialised software developer with major expertise in Bioinformatics and Artificial Intelligence (BIOX).
Beogenomics has been developing both on-prem and secure cloud-based data analysis solutions - helping customers design, build and run custom tailored genomics & proteomics pipelines. The start-up with amazing capability will be integrated into Manchester-based APIS, supporting the launch of a new BIOX Service Line as part of the company’s ongoing Biomarker Research and Development activities.
APIS develops new tests for the prediction, prevention, and diagnosis of disease from discovery to regulatory approval. The company’s business model is based on three pillars: biomarker diagnostics development, molecular diagnostic contract development, and applied bioinformatics.
Bioinformatics and Artificial Intelligence are key competencies adding value to APIS’ in-house capabilities and expanding APIS’ service offer profile. Using AI-enabled data mining, the company aims to identify novel biomarkers, targeting oncology, inflammatory, autoimmune, infectious disease, and inherited disease areas.
A tried and tested partner, Beogenomics will be fully integrated into the APIS workflow to strengthen the company’s business capacity needs, creating scope for a BIOX service line capable of delivering added value to APIS customers.
Dr Joachim Schorr, CEO of APIS, said: “We are delighted to announce our acquisition of Beogenomics, which offers strong operational and cultural fits. We look forward to welcoming the talented team and working together to expand our BIOX capacity internally, and build out a new, discrete, and externally-facing service line.”
“With the addition of Beogenomics’ proven expertise in bioinformatics – APIS can more effectively capture the exciting opportunities presented in the bioinformatics space,” added Ian Kavanagh, COO of APIS.
Sir Richard Leese, Leader of Manchester City Council (MCC), said: “Based on Manchester’s vision to establish a global genomics campus, the MCC investment into APIS already results in growth and very positive momentum as it brings together scientific expertise and cutting-edge technologies to develop novel biomarkers to help diagnose disease for patients in Greater Manchester and around the globe.”
The company’s structured R&D programme adopts a ‘portfolio model’ towards biomarker characterisation, linking the generated biomarker to data in relevant external datasets.
ISO certified APIS is led by a team of former employees from leading diagnostic companies and clinical laboratories from around the globe, providing more than 100 years of combined experience in biomarker research and offering an end-to-end IVD development service
For more information, visit www.apisassay.com